AKUMS Akums Drugs Q3 FY25 results (Oct–Dec 2024) and concall
Akums Drugs reported a mixed Q3 FY25 with total income declining to INR1,025 crores, but EBITDA and PAT showed growth, reaching INR136 crores and INR66 crores respectively. A significant highlight was securing a EUR 200 million CDMO contract for European markets, with an upfront payment of EUR 100 million expected. The API segment saw reduced losses, and the company continued to invest in R&D and capacity expansion, though overall capacity utilization remains low at 40%.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 |
|---|---|---|
| Revenue | 328 | 337 |
| EBITDA | 43 | 34 |
| Net profit | 50 | 41 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
